ENPP1 Inhibitor Design via Computational Docking
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for disorders associated with ENPP1 activity, such as cancer and viral infections, lack effective inhibitors that can specifically target ENPP1 without causing adverse side effects.
Innovation Solution
Development of compounds identified through structure-based computational docking and binding free energy analysis, which are designed to inhibit ENPP1 activity, thereby treating disorders like cancer and viral infections by modulating ENPP1 dysfunction.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments are used for disorders associated with ENPP1 activity, then they can be administered to patients, but they lack effective inhibition of ENPP1 and cause adverse side effects
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of ENPP1 inhibitors to optimize their binding affinity and selectivity. Through systematic variation of molecular parameters (substituents, ring structures, linkers), the invention achieves compounds with improved inhibitory potency against ENPP1 while reducing off-target effects that cause adverse side effects
Solution Approach 2:
The patent uses computational docking and binding free energy analysis as intermediary tools to predict and optimize the interaction between inhibitor compounds and ENPP1. These computational methods serve as mediators to screen and select compounds that will effectively inhibit ENPP1 before experimental validation, improving treatment reliability while minimizing harmful effects
2Reliability
If ENPP1 inhibitors are developed to specifically target ENPP1, then they can effectively treat disorders, but the complexity of identifying specific inhibitors increases
Solution Approach 1:
The patent applies preliminary action by performing computational docking and binding free energy calculations before experimental synthesis and testing. This preliminary computational screening narrows down the vast chemical space to a focused set of promising ENPP1 inhibitors, reducing the complexity of subsequent experimental identification while maintaining high specificity
Solution Approach 2:
The patent employs a multi-functional approach combining computational chemistry, molecular modeling, and experimental validation in a unified drug discovery platform. This universal methodology efficiently identifies specific ENPP1 inhibitors by integrating multiple techniques that work together to reduce overall complexity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds effectively inhibit ENPP1 activity, providing a therapeutic benefit in treating cancers and viral infections by eliciting an immunotherapeutic response, thus addressing the limitations of existing treatments.
Implementation Method 1
ENPP1 inhibition of STING pathway activation is critical for tumor control... The compounds effectively inhibit ENPP1 activity, providing a therapeutic benefit
Implementation Method 2
cyclic dinucleotides (CDNs), a substrate for ENPP1, stimulate innate immunity via STING-dependent activation of interferon genes
Data Source
Figure 1
Figure 2A~2B
Figure 3
AI summary
Substituted -3H-imidazo[4,5-c]pyridine and 1H-pyrrolo[2,5-c]pyridine series of novel Ectonucleotide Pyrophosphatase/Phosphodiesterase- 1 (ENPP1 ) and related compounds, which are useful as inhibitors of ENPP1; synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of using the compounds and compositions to treat disorders associated with dysfunction of the ENPP1.